Exploring the Impact of COVID-19 on Ulcerative Colitis Patients: A Lifestyle Perspective.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

Publication: 2018- : Basel, Switzerland : MDPI
Original Publication: Kaunas : Lietuvos gydytojų sąjunga

COVID-19* ; Colitis, Ulcerative*/complications ; Colitis, Ulcerative*/epidemiology; Humans ; Male ; Female ; Young Adult ; Adult ; SARS-CoV-2 ; Cross-Sectional Studies ; Life Style ; Vitamins

Background and Objectives : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the new coronavirus that caused the coronavirus disease 2019 (COVID-19) outbreak. Studies have increasingly reported the involvement of organs outside the respiratory system, including the gastrointestinal tract. Data on the association between COVID-19 and ulcerative colitis (UC) are lacking. Materials and Methods : In this one-centre cross-sectional study, 49 patients with UC from the Riga East Clinical University Hospital outpatient clinic were included from June 2021 to December 2021. The patients were divided into two groups according to their history of a confirmed positive or negative COVID-19 status. Data on their lifestyle, diet, and medications and the food supplements used by the patients were collected during interviews and analysed using the R 4.2.1 software. Results : Out of 49 patients, 33 (63.3%) were male and 13 (36.7%) were female, with a mean age of 32.33 ± 8.6 years. Fourteen patients (28.6%) had a confirmed COVID-19 infection in the last year. The most common COVID-19-related symptoms were a fever and rhinorrhoea. A third of patients followed the inflammatory bowel disease diet (16; 32.7%); out of these patients, 12 (34.3%) did not contract COVID-19 (OR: 0.78 (0.18; 2.98), p > 0.05). In the COVID-19-positive group, the majority of patients did not use vitamin D (11; 79% vs. 3; 21%, (OR: 0.38 (0.07; 1.51), p = 0.28) or probiotics (11; 78.6% vs. 3; 21.4%, OR: 1.33 (0.23; 6.28), p = 0.7). In the COVID-19-positive group, most patients did not smoke (12; 85.7% vs. 2; 14.3%, p = 0.475) and did not use alcohol (9; 64.3% vs. 5; 35.7%, OR: 0.63 (0.16; 2.57), p = 0.5). Most of the patients who participated in sports activities were COVID-negative (18; 51.4% vs. 6; 42.9%, p = 0.82). Conclusions : There were no statistically significant differences in the use of food supplements, probiotics, or vitamins; the lifestyle habits; or the COVID-19 status in patients with UC.

Lancet Gastroenterol Hepatol. 2020 Jul;5(7):644-645. (PMID: 32339473)
Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):267-273. (PMID: 34191758)
JAMA Netw Open. 2021 Feb 1;4(2):e210369. (PMID: 33576820)
Nutrients. 2022 Jul 26;14(15):. (PMID: 35893907)
Inflamm Bowel Dis. 2023 Feb 1;29(2):217-221. (PMID: 35385102)
BMC Gastroenterol. 2023 Jul 5;23(1):230. (PMID: 37407913)
Aging (Albany NY). 2020 Jul 3;12(13):12468-12478. (PMID: 32628131)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
J Med Virol. 2020 May;92(5):479-490. (PMID: 32052466)
Pan Afr Med J. 2021 Feb 15;38:168. (PMID: 33995775)
Addiction. 2021 Jun;116(6):1381-1388. (PMID: 33006789)
Adv Ther. 2023 May;40(5):1975-2014. (PMID: 36928496)
Nutrients. 2022 Oct 10;14(19):. (PMID: 36235869)
Cureus. 2022 Dec 3;14(12):e32153. (PMID: 36601162)
Inflamm Bowel Dis. 2021 Jul 27;27(8):1224-1229. (PMID: 33043977)
Nutrients. 2020 Jun 03;12(6):. (PMID: 32503173)
Clin Infect Dis. 2023 Jan 13;76(2):185-191. (PMID: 36367144)
Expert Rev Clin Pharmacol. 2022 Oct;15(10):1243-1252. (PMID: 36047032)
Front Neurosci. 2021 Jul 02;15:694446. (PMID: 34276298)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Medicine (Baltimore). 2022 Dec 23;101(51):e32386. (PMID: 36595802)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
PLoS One. 2022 Jul 6;17(7):e0268396. (PMID: 35793346)
Int J Antimicrob Agents. 2020 Mar;55(3):105924. (PMID: 32081636)
Nutrients. 2022 Nov 20;14(22):. (PMID: 36432593)
Rev Med Virol. 2023 Mar;33(2):e2414. (PMID: 36504172)
Endocr Pract. 2021 Dec;27(12):1242-1251. (PMID: 34653608)
Turk J Gastroenterol. 2022 May;33(5):387-396. (PMID: 35678796)
Nutrients. 2019 Sep 04;11(9):. (PMID: 31487891)
Nutrients. 2020 May 21;12(5):. (PMID: 32455696)
Science. 2000 Aug 25;289(5483):1352-5. (PMID: 10958782)
Signal Transduct Target Ther. 2022 Apr 29;7(1):143. (PMID: 35487886)
PLoS One. 2023 Apr 12;18(4):e0283233. (PMID: 37043451)
Nutrients. 2017 Jun 27;9(7):. (PMID: 28654017)
J Diet Suppl. 2023;20(2):199-217. (PMID: 36476207)
Cureus. 2023 Mar 18;15(3):e36325. (PMID: 37077615)
Gut. 2021 Apr;70(4):635-640. (PMID: 33472895)
J Crohns Colitis. 2020 Dec 2;14(12):1702-1708. (PMID: 32564068)
Dig Liver Dis. 2022 Oct;54(10):1449-1451. (PMID: 35973931)
Eur Addict Res. 2020;26(6):309-315. (PMID: 32961535)
Front Horm Res. 2017;48:121-132. (PMID: 28245457)
Clin J Gastroenterol. 2023 Apr;16(2):187-192. (PMID: 36417106)
Gastroenterology. 2020 Jul;159(1):350-357. (PMID: 32283100)
World J Gastroenterol. 2021 Jul 14;27(26):4160-4171. (PMID: 34326616)
World J Gastroenterol. 2023 Nov 7;29(41):5668-5682. (PMID: 38077160)
Intern Med. 2022 May 1;61(9):1329-1336. (PMID: 35228418)
Clin Nutr. 2020 Jun;39(6):1631-1638. (PMID: 32305181)
Eur Respir Rev. 2023 Mar 8;32(167):. (PMID: 36889786)
Inflamm Bowel Dis. 2022 May 4;28(5):710-719. (PMID: 34137449)
Inflamm Bowel Dis. 2019 May 4;25(6):1061-1065. (PMID: 30358844)
Intern Emerg Med. 2020 Aug;15(5):845-852. (PMID: 32385628)
C R Biol. 2020 Jun 05;343(1):33-39. (PMID: 32720486)
Gastroenterol Clin North Am. 2023 Mar;52(1):103-113. (PMID: 36813419)
Int J Environ Res Public Health. 2020 Jun 07;17(11):. (PMID: 32517294)
J Crohns Colitis. 2021 Aug 2;15(8):1376-1386. (PMID: 33721882)
Inflamm Bowel Dis. 2022 Aug 1;28(8):1265-1279. (PMID: 34718595)
BMJ. 2017 Feb 15;356:i6583. (PMID: 28202713)
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S798-S806. (PMID: 32722754)
J Gastroenterol. 2022 Mar;57(3):174-184. (PMID: 35089397)

1.1.1.1/21/A/029 European Regional Development Fund; 1.1.1.1/21/A/029 European Regional Development Fund

Keywords: COVID-19; cross-sectional study; lifestyle factors; ulcerative colitis

0 (Vitamins)

Date Created: 20240126 Date Completed: 20240129 Latest Revision: 20240129

20240129

PMC10819492

10.3390/medicina60010182

38276061